Specifically, ARL4C expression was lower in ACC, breast cancer (BRCA), KICH, prostate adenocarcinoma (PRAD), skin cutaneous melanoma (SKCM), and thyroid carcinoma (THCA) compared to normal tissues. This evidence concerns the gene ARL4C and thyroid gland carcinoma.